Mike Sennett is partner at Jones Day, based in Chicago. He practices antitrust law with an emphasis on the antitrust aspects of mergers, acquisitions, and joint ventures ; antitrust litigation ; civil investigations before the United States Department of Justice, the Federal Trade Commission, and state attorneys general ; and criminal and cartel antitrust matters, including grand jury proceedings. Mike handles complex antitrust cases in courts throughout the United States, including before the Judicial Panel on Multidistrict Litigation, and antitrust enforcement matters with the competition agencies. He also counsels clients on the antitrust aspects of intellectual property licensing and related patent matters, strategic alliances and collaborations, pricing and price discrimination, distribution, advertising and marketing practices, as well as Hatch-Waxman Act strategies. Mike Sennett serves as antitrust counsel to a number of multinational corporations and businesses operating domestically and globally. His industry experience includes pharmaceuticals, biotechnologies, medical devices, pharmaceutical benefit services, steel, automotive, building products, farm equipment, consumer products, mining, water and wastewater technologies and services, health care services, transportation, financial services, and communications. Representative corporate clients include Arctic Glacier, Astellas Pharma, Baxter International, Boehringer Ingelheim, Cardinal Health, CVS Caremark, Edwards Lifesciences, Fortune Brands Home & Security, and Potash Corporation of Saskatchewan. Mike is on the adjunct law faculty at Loyola University Chicago where he teaches antitrust law. He is a member of the board of advisors of the Institute for Consumer Antitrust Law Studies and the Midwest Antitrust Colloquium. He has written extensively on antitrust law matters for academic and trade journals and delivered addresses on competition issues for conferences in the U.S. and abroad.
122
This article has been nominated for the 2020 Antitrust Writing Awards. Click here to learn more about the Antitrust Writing Awards. In Short The Situation : The Federal Trade Commission ("FTC") recently filed a rare monopolization case, alleging that a health information technology company (...)
230
The D.C. Circuit has rejected a challenge by the Pharmaceutical Research and Manufacturers of America ("PhRMA") to an FTC rule that makes the HSR Act reporting requirements cover pharmaceutical patent licenses that transfer "all commercially significant rights." The rule, adopted in 2013, (...)
750
With the Supreme Court set to address the validity of "reverse payment" settlements of pharmaceutical patent litigation, the FTC released a summary of its new report, announcing that in 2012 drug companies entered "a record number" of such settlements. However, the underlying data and analysis (...)
144
The FTC has brought an FTC administrative action alleging price fixing and other anticompetitive behavior involving three of the largest U.S. suppliers of ductile iron pipe fittings (DIPF), which are used in municipal water systems. It now has published for public comment a proposed consent (...)
185
This week the U.S. Supreme Court announced it would not review a Third Circuit decision (Animal Science) that made it easier for antitrust plaintiffs to bring claims in U.S. courts for conduct occurring overseas under the Foreign Trade Antitrust Improvements Act (“FTAIA”). The Supreme Court’s (...)
181
This article has been nominated for the 2012 Antitrust Writing Awards. Click here to learn more about the Antitrust Writing Awards. Recent decisions by the Third Circuit and the Northern District of California make it easier for plaintiffs to bring claims under the Foreign Trade Antitrust (...)
180
This article has been nominated for the 2012 Antitrust Writing Awards. Click here to learn more about the Antitrust Writing Awards. Recent decisions by the Third Circuit and the Northern District of California make it easier for plaintiffs to bring claims under the Foreign Trade Antitrust (...)
